Equities researchers at Griffin Securities assumed coverage on shares of Heat Biologics, Inc. (NASDAQ:HTBX) in a research note issued on Tuesday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $2.25 price target on the biopharmaceutical company’s stock. Griffin Securities’ target price would indicate a potential upside of 263.43% from the company’s current price. Griffin Securities also issued estimates for Heat Biologics’ Q3 2017 earnings at ($0.09) EPS, Q4 2017 earnings at ($0.07) EPS, FY2017 earnings at ($0.35) EPS, Q1 2018 earnings at ($0.07) EPS, Q2 2018 earnings at ($0.07) EPS, Q3 2018 earnings at ($0.05) EPS, Q4 2018 earnings at ($0.05) EPS, FY2018 earnings at ($0.23) EPS, FY2019 earnings at ($0.19) EPS, FY2020 earnings at ($0.25) EPS and FY2021 earnings at $0.17 EPS.

A number of other equities analysts have also recently commented on the company. Zacks Investment Research upgraded Heat Biologics from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a report on Thursday, May 25th. ValuEngine cut Heat Biologics from a “sell” rating to a “strong sell” rating in a report on Thursday, July 13th. Finally, Noble Financial restated a “buy” rating on shares of Heat Biologics in a report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $1.67.

Heat Biologics (HTBX) traded down 0.3220% during mid-day trading on Tuesday, hitting $0.6191. The company had a trading volume of 1,007,001 shares. The company’s market capitalization is $22.16 million. Heat Biologics has a 52-week low of $0.46 and a 52-week high of $3.35. The company has a 50-day moving average price of $0.53 and a 200 day moving average price of $0.68.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/17/griffin-securities-initiates-coverage-on-heat-biologics-inc-htbx.html.

Institutional investors have recently made changes to their positions in the stock. KCG Holdings Inc. boosted its holdings in Heat Biologics by 35.3% during the 1st quarter. KCG Holdings Inc. now owns 175,769 shares of the biopharmaceutical company’s stock valued at $156,000 after acquiring an additional 45,831 shares during the period. Vanguard Group Inc. boosted its holdings in Heat Biologics by 11.9% during the 2nd quarter. Vanguard Group Inc. now owns 661,388 shares of the biopharmaceutical company’s stock valued at $403,000 after acquiring an additional 70,290 shares during the period. Finally, Sabby Management LLC purchased a new position in Heat Biologics during the 1st quarter valued at about $2,176,000. Institutional investors own 8.74% of the company’s stock.

Heat Biologics Company Profile

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.